Nano Dimension and Infinite Epigenetics announced a proposed business combination to create an AI-powered preventive health and diagnostics company. Nano Dimension's board selected Infinite Epigenetics after evaluating approximately 20 opportunities, citing its established epigenetics science, CLIA-certified laboratory, 120,000+ biological samples, and commercial revenue. The companies addressed concerns from shareholder Murchinson Ltd., emphasizing the transaction's strategic rationale, capital deployment plan, and board expertise. The combination values Nano at net cash plus a 20% premium and will be subject to shareholder vote.

Ventripoint Diagnostics announced support for the newly formed Global Congenital Heart Disease Alliance (GCHDA), positioning its AI-powered VMS+ cardiac imaging platform to address a critical global healthcare gap. With 16 million people living with congenital heart disease and over 90% of children in lower-income countries lacking timely care, Ventripoint's vendor-agnostic technology delivers MRI-level accuracy from standard echocardiograms. The alliance will fund and place four VMS+ units, signaling commercial validation in a rapidly growing AI cardiology market projected to reach $14.2 billion by the mid-2030s.

Tempus AI is positioning itself as a healthcare AI winner with its growing data platform, AI tools, FDA progress, and pharma partnerships. However, the stock already reflects high expectations, making execution critical for investors seeking meaningful upside.

The Nasdaq 100 fell 0.7% as chip stocks stumbled, with Broadcom cratering 15% despite beating earnings due to weak AI-chip revenue guidance. The Dow Jones rallied 1.7% on defensive and financial strength, while the S&P 500 remained flat. Bitcoin hit a 4-month low at $61,310. Other tech stocks like CrowdStrike, Ciena, and Five Below also declined despite beating estimates, reflecting a 'beat-and-bleed' market dynamic. Healthcare and financial stocks led gains.

Bristol-Myers Squibb announced a strategic partnership with Anthropic to deploy advanced AI capabilities across its operations, focusing on drug discovery and development in oncology and neuroscience. The collaboration will leverage AI, multimodal data, and Tempus' analytical platform to streamline research, clinical development, and manufacturing processes, aiming to improve trial design and patient population identification.

Ventripoint Diagnostics has achieved multiple validation milestones in early 2026, including submitting its VMS+ 4.0 system to China's NMPA for expedited review, exhibiting at Europe's largest congenital cardiology conference, and establishing commercial partnerships for hospital deployment. The company is capitalizing on a shifting procurement environment where hospitals now demand economic proof alongside clinical accuracy for AI cardiac imaging solutions.

Tempus AI and Bristol Myers Squibb announced an expanded collaboration to use AI and real-world data to improve clinical trial design across oncology and neuroscience programs. The partnership leverages Tempus' Lens platform to analyze patient records and aims to strengthen drug development strategies, identify appropriate patient populations, and accelerate treatment delivery, building on their existing Next Pathways program.

The healthcare industry is shifting toward data-driven, precision medicine models powered by AI and genomic data. Three companies are positioned to lead this transformation: Tempus AI is building a healthcare data platform with network effects; Recursion Pharmaceuticals is accelerating drug discovery through automation and machine learning; and Axsome Therapeutics is gaining traction with fast-acting CNS treatments, particularly its antidepressant Auvelity.

Pathos AI announced the acquisition of a majority stake in Belgium-based DeuterOncology, which is developing DO-2, a third-generation MET kinase inhibitor for MET-altered cancers. The asset was identified through Pathos's Foundry AI platform. DO-2 demonstrated 100% tumor shrinkage in Phase 1 trials with a superior safety profile and significantly lower peripheral edema rates (5%) compared to competitors (62-82%), with patent exclusivity extending to December 2040.

The AI clinical trial protocol feasibility tool market is experiencing rapid expansion, growing from $0.83 billion in 2025 to $1.06 billion in 2026 with a 27.3% CAGR. The market is projected to reach $2.76 billion by 2030, driven by increasing protocol complexity, precision medicine focus, decentralized trial designs, and AI-enabled protocol optimization. Key players include IQVIA Holdings, SAS Institute, Veeva Systems, and Tempus AI, with North America leading and Asia-Pacific emerging as the fastest-growing region.

A wave of momentum swept through large-cap stocks during the week of April 13-17, 2026, with ten standout performers. Notable gainers include Avis Budget Group (71.48% jump driven by short squeeze), IonQ (62.86% surge following DARPA contract award), Oklo (33.35% rise on nuclear power narrative), Robinhood (33.22% gain from bullish analyst outlook and crypto rebound), and Strategy Inc (31.86% increase). Other top performers include Tempus AI, Credo Technology, Affirm Holdings, and Summit Therapeutics, with gains ranging from 28-31%.

Tempus AI (NASDAQ: TEM) shares rose 7.30% to $49.34 following the announcement that 31 abstracts were accepted for presentation at the AACR Annual Meeting 2026. The presentations highlight emerging biomarkers and real-world evidence in cancer treatment, including studies on MSI-related gene fusions in colorectal cancer, KMT2C mutations linked to platinum therapy benefits, and SCLC subtype variability. However, Jefferies initiated coverage with an Underperform rating and $35 price target.